Authors: Dhodapkar, MV Jacobson, JL Gertz, MA Rivkin, SE Roodman, GD Tuscano, JM Shurafa, M Kyle, RA Crowley, JJ Barlogie, B

Citation: Mv. Dhodapkar et al., Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003), BLOOD, 98(1), 2001, pp. 41-48

Authors: Elias, L Lew, D Figlin, RA Flanigan, RC Thompson, ME Triozzi, PL Belt, RJ Wood, DP Rivkin, SE Crawford, ED

Citation: L. Elias et al., Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma - A southwest oncology group phase II study, CANCER, 89(3), 2000, pp. 597-603

Authors: Haas, GP Blumenstein, BA Gagliano, RG Russell, CA Rivkin, SE Culkin, DJ Wolf, M Crawford, ED

Citation: Gp. Haas et al., Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: A Southwest Oncology Group study, J UROL, 161(6), 1999, pp. 1823-1825

Authors: Rothenberg, ML Cox, JV DeVore, RF Hainworth, JD Pazdur, R Rivkin, SE Macdonald, JS Geyer, CE Sandbach, J Wolf, SL Mohrland, JS Elfring, GL Miller, LL Von Hoff, DD

Citation: Ml. Rothenberg et al., A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma, CANCER, 85(4), 1999, pp. 786-795

Authors: Meyers, FJ Lew, D Lara, PN Williamson, S Marshall, E Balcerzak, SP Rivkin, SE Samlowski, W Crawford, ED

Citation: Fj. Meyers et al., Phase II trial of edatrexate in relapsed or refractory germ cell tumors: ASouthwest Oncology Group study (SWOG 9124), INV NEW DR, 16(4), 1998, pp. 347-351